he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-05-03丙泊酚诱发无痛交通流量术后癫痫持续状态1例
- 2022-05-022013年世界性抗癫痫联合会抗癫痫药使用指南
- 2022-04-25隐源性癫痫发生率翻倍
- 2022-04-21隐源性痉挛死亡率翻倍
- 2022-04-13药学版元宵灯谜 看你能猜对几个问题
- 2022-04-12Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 癫痫治疗障碍仍难以克服
- Medpage Today:不同类型的抗癫痫药物更有利
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 北京哪家癫痫医院排名好,成本低
- 抗癫痫药物预防新发癫痫:任重而道远
- 副教授赵倩华谈到了认知障碍的早期诊断策略
- 2013国际抗癫痫联合会抗癫痫药用指南
- 治疗脑炎后遗症的方法有哪些?
- 羊角风有什么症状?
- 黑芝麻的营养价值 吃黑芝麻的好处
- UCB的Vimpat癫痫新适应症在美国获批
- 月经性癫痫患者妊娠期癫痫控制更好
- 2015第31届国际癫痫大会(IEC)
- FDA批准Aptiom用于治疗患者癫痫发作
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 综述:癫痫持续状态诊治最新进展
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫患者手术评估新型工具
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 老年人癫痫的症状是什么?
- 油炸刀鱼 酥脆的美味食物
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 北京癫痫医院治疗费用
- 癫痫治愈费用
- 癫痫猝死:凶手是谁?
- 脑梗死的症状是什么有这些前兆要谨慎
- 异地就医体验升级!而今将进一步扩大门诊费用跨省直接结算试点范围
- 小儿癫痫病要怎么用药呢
- 癫痫病能病患好吗
- 癫痫病的早呕吐是什么样的
- 向对侧转移:部分性癫痫持续稳定状态
- 抑止青少年癫痫的病因
- PLoS ONE:新的合成蛋白能并能激活免疫系统抵御流感
- 《中国慢性疾病防治基层医生诊疗手册:神经病学修订版》定稿出版
- 最有效用药癫痫病的药是哪些
- 怎么治疗少年稳定型癫痫病最难
- 中医学治疗癫痫病比较好医院
- 癫痫病发病根本是怎么回事
- 大脑胶质瘤释放的谷氨酸盐可诱发癫痫